- LUVOX(R) CR Approved and Launched
- Screening Closed in First Phase III Fibromyalgia Clinical Trial
PALO ALTO, Calif., May 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced financial results for the quarter ended March 31, 2008.
Total revenues for the quarter ended March 31, 2008 were $14.6 million, compared to $14.1 million for the quarter ended March 31, 2007. XYREM(R) (sodium oxybate oral solution) net sales for the first quarter of 2008 increased 32 percent to $11.3 million, compared with $8.6 million for the first quarter of 2007.
Once-Daily LUVOX CR(R) (fluvoxamine maleate) Extended-Release Capsules was approved by the U.S. Food and Drug Administration (FDA) on February 28, 2008 for the treatment of both obsessive compulsive disorder (OCD) and social anxiety disorder (SAD), and the product was shipped to wholesalers late in the first quarter.
"The launch of LUVOX CR in the U.S. is progressing very well," said Robert Myers, President of Jazz Pharmaceuticals. "Our commercial team is focused on introducing this important new treatment option to physicians for their patients with OCD and SAD."
"We are off to a great start in 2008, with significant product development achievements in addition to our commercial success," said Samuel Saks, M.D., Chief Executive Officer. "We recently completed screening of subjects in the first of our Phase III pivotal studies of JZP-6 for the treatment of fibromyalgia syndrome, a key milestone in this program. We look forward to obtaining results from this Phase III trial in the fourth quarter of 2008."
Research and development expenses for the first quarter of 2008 were $21.2 million, compared to $14.9 million for first quarter of 2007. The increase primarily reflects higher expenses associated with later stage development programs, particularly JZP-6.
Selling, general and administrative expenses for first quarter of 2008 were $32.8 million, compared to $14.3 million for the first quarter of 2007. The increase was primarily due to spending in preparation for the launch of LUVOX CR, increased headcount and higher expenses to support the larger sales force.
Net loss for the first quarter of 2008 was $46.7 million, compared to a $19.6 million net loss for the first quarter of 2007.
Jazz Pharmaceuticals' unrestricted cash and marketable securities
balance as of March 31, 2008 was $105.2 million. During the quarter ended
March 31, 2008, net cash used in operating activities was $38.2 million.
-- In late March 2008, approximately $3.0 million of LUVOX CR commercial
product was shipped to wholesalers. As is common for new
pharmaceutical product launches, no LUVOX CR net sales revenue was
recognized in the first quarter of 2008.
-- In mid-April 2008, Jazz Pharmaceuticals' sales team of approximately
200 field-based professionals began communicating with psychiatrists
and select primary care physicians about the unique attributes of
LUVOX CR for OCD and SAD patients. Sales professionals are providing
samples of LUVOX CR in 100 mg and 150 mg doses. Jazz Pharmaceuticals
is also supporting non-branded disease awareness campaigns to
highlight the importance of correctly diagnosing and treating OCD and
-- Approval and launch of LUVOX CR triggered a total of $41.0 million in
milestone payments to Solvay Pharmaceuticals, $10.0 million of which
was paid in March 2008.
-- On April 25, 2008, screening of subjects was closed in the first of
Jazz Pharmaceuticals' two Phase III clinical trials of JZP-6 (sodium
oxybate) in fibromyalgia. The enrollment goal of 525 subjects has
been achieved in the first trial, and enrollment is expected to be
completed in the next several weeks. Top-line results for the first
trial are expected in the fourth quarter of 2008. Enrollment is
progressing in the second Phase III clinical trial of JZP-6 at
clinical sites in the U.S. and Europe.
-- On March 18, 2008, Jazz Pharmaceuticals announced the expansion of its
senior term debt under an agreement with an affiliate of Lehman
Brothers and certain other lenders. The transaction closed with
$40 million of gross proceeds, expanding the senior debt outstanding
from $80 million to $120 million. Jazz Pharmaceuticals has an option
under the agreement, through January 31, 2009, to borrow an additional
$30 million if sales of the company's products reach certain levels by
the end of 2008.
-- On May 8, 2008, Jazz Pharmaceuticals announced it had entered into a
Committed Equity Financing Facility (CEFF) with Kingsbridge Capital
Limited, a private investment group, in which Kingsbridge committed to
provide up to $75 million of capital through the purchase of
newly-issued shares of Jazz Pharmaceuticals' common stock. Under the
terms of the three-year agreement, Jazz Pharmaceuticals will determine
the exact timing and amount of any CEFF financings, subject to certain
conditions. The arrangement allows Jazz Pharmaceuticals to raise
capital, at its discretion, to support the company's commercial,
research and development and general corporate activities.
Jazz Pharmaceuticals will host an investor conference call and live audio webcast to discuss its financial results and provide a business update on its commercial and development activities on May 13, 2008 commencing at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The live webcast may be accessed on Jazz Pharmaceuticals' website at http://www.JazzPharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. An archived version of the webcast will be available through May 27, 2008. Investors may participate in the conference call by dialing 800-901-5259 in the U.S., or 617-786-4514 outside the U.S., and entering passcode 91585353. A replay of this call will be available until May 27, 2008 by phone at 888-286-8010 (U.S.), or 617-801-6888 (international), using the passcode 89402608.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information see http://www.JazzPharmaceuticals.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but
not limited to, statements related to the commercial launch of LUVOX CR,
the continued development of Jazz Pharmaceuticals' product candidates and
the timing of clinical study results. These forward-looking statements are
based on the company's current expectations and inherently involve
significant risks and uncertainties. Jazz Pharmaceuticals' actual results
and the timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to the
launch of LUVOX CR; risks related to the development of Jazz
Pharmaceuticals' product candidates, including the risk that study or
clinical trial results may require Jazz Pharmaceuticals to discontinue the
development of one or more product candidates; risks related to the
uncertain and time-consuming regulatory approval process; and risks
relating to the need for additional funds. These and other risk factors are
discussed under "Risk Factors" in the Annual Report on Form 10-K for the
year ended December 31, 2007 filed by Jazz Pharmaceuticals with the
Securities and Exchange Commission on March 31, 2008. Jazz Pharmaceuticals
undertakes no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future events or
changes in its expectations.
JAZZ PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
Three Months Ended March 31,
Product sales, net $13,984 $11,625
Royalties, net 365 211
Contract revenues 285 2,252
Total revenues 14,634 14,088
Cost of product sales (excluding
amortization of acquired developed
technology) 2,298 2,003
Research and development 21,243 14,867
Selling, general and administrative 32,780 14,339
Amortization of intangible assets 2,121 2,362
Total operating expenses 58,442 33,571
Loss from operations (43,808) (19,483)
Interest income 897 1,091
Interest expense (3,787) (3,268)
Other expense (12) (3,069)
Gain on sale of product rights - 5,145
Net loss $(46,710) $(19,584)
Net loss per share, basic and
diluted $(1.97) $(851.48)
Weighted-average common shares used
in computing net loss per share, basic
and diluted 23,743 23
JAZZ PHARMACEUTICALS, INC.
SUMMARY OF PRODUCT SALES, NET
Three Months Ended March 31,
Xyrem $11,341 $8,624
Antizol 2,643 2,636
Cystadane - 365
Total $13,984 $11,625
JAZZ PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, December 31,
Cash and cash equivalents $100,771 $102,945
Restricted cash 1,998 1,939
Marketable securities 4,410 -
Accounts receivable, net 5,310 5,389
Inventories 2,200 2,213
Prepaid expenses 3,210 3,224
Other current assets 1,346 381
Total current assets 119,245 116,091
Property and equipment, net 3,875 3,941
Intangible assets, net 74,919 36,040
Goodwill 38,213 38,213
Long-term restricted cash and
investments - 12,000
Other long-term assets 2,766 1,269
Total assets $239,018 $207,554
LIABILITIES AND STOCKHOLDERS' EQUITY
Line of credit $3,180 $3,459
Accounts payable 8,915 2,856
Accrued liabilities 30,133 29,047
Purchased product rights liability 31,000 -
Deferred revenue 1,494 1,494
Total current liabilities 74,722 36,856
Non-current portion of deferred revenue 12,183 12,468
Liability under government settlement 13,063 14,881
Senior secured notes 113,367 75,116
Common stock subject to repurchase 13,241 13,241
Stockholders' equity 12,442 54,992
Total liabilities and stockholders'
equity $239,018 $207,554
|SOURCE Jazz Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved